China
Africa
Explore chapters and articles related to this topic
Enrich to Rich—an Indigenous Model to Combat COVID-19
Published in Suman Lata Tripathi, Kanav Dhir, Deepika Ghai, Shashikant Patil, Health Informatics and Technological Solutions for Coronavirus (COVID-19), 2021
When traveling abroad, especially in countries where there is an outbreak of the virus, you should boost your immunity a lot and keep medicines for colds, coughs and fevers close by. At most airports, train stations and bus stations, passengers infected with the virus are sent back or allowed after a health check-up, so avoid traveling if you have a fever, chills and cough. People who are in close contact with patients infected with the corona virus should get themselves examined immediately. If you have a fever, chills, cough and you have difficulty breathing, seek immediate medical attention. When eating out, make sure that food safety, food handling and hygiene are taken care of in hotels. Also here is a bonus tip, this recipe will boost your immunity and keep you safe. The masala tea recipe is perfect for tea flavor as well as nutrients like Vitamin A, Vitamin C and B vitamins. It has antioxidant, antifungal and antiinflammatory properties that help the human body to repair and boost the immune system. Note: This action is not recommended for those who have breast cancer, uterine cancer or any disease caused by excessive estrogen.
Precision or Personalized Medicine for Cancer Chemotherapy: Is There a Role for Herbal Medicine?
Published in Shaker A. Mousa, Raj Bawa, Gerald F. Audette, The Road from Nanomedicine to Precision Medicine, 2020
Zhijun Wang, Xuefeng Liu, Rebecca Lucinda Ka Yan Ho, Christopher Wai Kei Lam, Moses Sing Sum Chow
This is a two-dimensional (2D) culture technique of patient cancer cells from tissue samples and it can be utilized for determination of drug sensitivity (e.g., using similar drug concentration exposure as that occurred in patients receiving the same drug). When comparing retrospectively the drug sensitivity from such in vitro determination has been found to correspond well to the therapeutic response in patients (sensitivity and specificity of 88.2% and 80.6% respectively with a predictive accuracy of about 84.1%) for a wide variety of cancer cells tested including lung, breast, gastric, esophagus [34]. Furthermore, the CD-DST drug sensitive results have been found to provide a better prediction to clinical response of gastric cancer, non-small cell lung cancer, or ovarian/uterine cancer when compared to those with drug resistant test results [35–37]. One important limitation of this method is the need to obtain >104 cells from biopsy samples for cell culture.
Nanomedicine Clinical and Preclinical Use
Published in Bertrand Henri Rihn, Biomedical Application of Nanoparticles, 2017
Roudayna Diab, Sanghoon Kim, Ileana-Alexandra Pavel, Nadia Canilho, Fernanda Bianca Haffner, Sijin Li, Alain Celzard, Mihayl Varbanov, Emmanuel Lamouroux, Andreea Pasc
Silica ultra-small NPs (3–5 nm) containing fluorescent dye, called cornel-dots, were recently introduced in Phase I clinical trial stage using PET imaging (ClinicalTrials.gov identifier: NCT01266096). Silica NPs were functionalized with 124I-labelled cRGD peptide, as a targeting ligand directed against αvβ3 integrin-expressing melanoma (Benezra et al., 2011). Pharmacokinetic studies showed that these NPs are fully removed from the body by renal clearance. Currently, these multifunctional particles are undergoing clinical evaluation for imaging of diseased lymph nodes during the surgical procedure in head and neck melanoma, breast cancer, and uterine cancer patients (ClinicalTrials.gov identifier: NCT02106598). The advantages of multifunctional NPs are discussed in the following sections.
Serum Levels Evaluation of TMSB10 and Endocan in Breast Cancer Patients and In-Vitro Study of Chrysin Effect on These Markers in MCF-7 cell line
Published in Egyptian Journal of Basic and Applied Sciences, 2023
Nada E. Hammouda, Yara A. Samra, Ziad Emarah, Amal M. El-Gayar
In cancer patients, the serum protein END exists in the polysaccharide form. END holds a core protein that composed of 165 amino acids and a mono-mucopolysaccharides chain linked covalently to the 137th serine residue (DS chains), which is a vital constituent of the functional structure of END [29,30]. Numerous studies have identified high END expression in uterine cancer, BC, and other tumors. Furthermore, prognosis of cancer, angiogenesis and metastasis was confirmed to be allied with END expression. Most studies showed that END modulates cancer by tumor-related inflammation, angiogenesis, lymph-angiogenesis and the tumor cells themselves. Subsequently, Endocan may be a promising target for cancer prognosis and diagnosis [12,31–33]. Consistent with previous researches, this study demonstrated that END levels in the sera of BC patients were significantly higher than those of healthy controls.
Efficacy of polyvinylpyrrolidone-capped gold nanorods against 7,12 dimethylbenz(a)anthracene-induced oviduct and endometrial cancers in albino rats
Published in Egyptian Journal of Basic and Applied Sciences, 2023
Hend Gamal, Walid Tawfik, Hassan H El-Sayyad, Heba Mohamed Fahmy, Ahmed N. Emam, Heba A El-Ghaweet
Those with uterine cancer also experience this. Furthermore, the bulk of the tumors that advanced in this rat example were adenocarcinomas as shown by these findings and past research [34–37], a well-known pathogenic subtype of human uterine cancer. In this rat model, some pathogenic features of human uterine cancer are duplicated. Many problems still need to be resolved in the future. These elements impact the pharmacokinetics, biodistribution and toxicity of GNP.
Uterine bioimpedance combined with artificial intelligence as a means of cancer detection
Published in Journal of Medical Engineering & Technology, 2021
Shabnam Gupta, Andres Vargas, Gary Saulnier, Jonathan Newell, Christian Faaborg-Andersen, Robert S. Kelley
Uterine cancer is the most common gynaecologic malignancy, affecting 1–2% of women in the United States, and is increasing nationally [1]. The incidence is highest in women between 60–70 years old, but 2–5% of cases may occur before the age of 40 years. Between 2006 and 2012, there was a 10% increase in uterine cancer cases. Potential factors contributing to this rise include increasing prevalence of obesity, decreasing use of menopausal hormone therapy with progestins, increasing prevalence of diabetes, increased nulliparity, and increased life-expectancy [2]. Unlike breast and cervical cancer, there are currently no CDC recommended screening guidelines for uterine cancer. Endometrial sampling can cause bleeding, pain, pelvic infection, and even perforation of the uterine wall [3]. Additionally, the sensitivity of endometrial biopsy reported in the literature ranges widely, from 62 to 99.2% [4]. These values vary depending on the endometrial thickness, tissue histology, percentage of the endometrium affected by disease, and the patient’s menopausal status. Even in patients who tolerate this procedure well, less than 50% of the endometrium is sampled, with reported failure rates of 31–100% in detecting focal lesions [5]. This problem is compounded by data showing that screening of asymptomatic women by transvaginal ultrasonography produces a substantial number of false-positives, unnecessarily subjecting patients to follow-up biopsy and its associated complications [6]. Occult malignancy in the uterine body may complicate procedures such as supracervical hysterectomy, myomectomy, and Lefort colpocleisis. Minimally invasive procedures are especially at risk due to potential spillage of cells depending on method of tissue removal [7–9]. While a patient’s treatment must be individualised based on their specific risk factors, the estimated risk of occult malignancy among the general population is estimated to be 1 in 305 to 1 in 360 for uterine sarcoma, and 1 in 770 to 1 in 10,000 for leiomyosarcoma [10,11]. These issues drive the challenge to develop a method for detecting occult malignancy.